Identification

Name
Potassium Chloride
Accession Number
DB00761  (APRD01322)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

Structure
Thumb
Synonyms
  • [KCl]
  • Chlorid draselny
  • Chloride of potash
  • Kaliumchlorid
  • KCl
  • Monopotassium chloride
  • Muriate of potash
  • Sylvite
External IDs
B1653 / E 508 / E-508 / INS NO.508 / INS-508 / NSC-77368
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
K + 45Liquid251.6 gHemodialysisBaxter Laboratories1990-12-31Not applicableCanada
K C1-rougierLiquid750 mgOralRougier Pharma Division Of Ratiopharm Inc1967-12-311999-09-27Canada
K Lor Granules 20meqPowder, for solution1.5 gOralAbbott1979-12-312008-06-06Canada
K-durTablet, extended release1.5 gOralMerck Ltd.1989-12-312014-12-04Canada
K-lyte ClPowder, for solution1.86 gOralWell Spring Pharmaceutical Corporation1995-12-312009-02-23Canada
K-med 900 Tab 900mgTablet900 mgOralLaboratoire Riva Inc1989-12-312008-07-30Canada
K-TabTablet, film coated, extended release750 mg/1OralAbbvie1980-06-09Not applicableUs00074 7804 13 nlmimage10 e80df41f
K-TabTablet, film coated, extended release750 mg/1OralAphena Pharma Solutions Tennessee, Inc.1980-06-09Not applicableUs
K-TabTablet, film coated, extended release750 mg/1OralAbbvie2017-06-01Not applicableUs
K-TabTablet, film coated, extended release1500 mg/1OralAbbvie1980-06-09Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Klor Con MTablet, extended release750 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-11-20Not applicableUs
Klor Con MTablet, extended release1500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-11-20Not applicableUs00245 0058 01 nlmimage10 bb345de2
Klor-con MTablet, extended release1500 mg/1OralAphena Pharma Solutions Tennessee, Inc.2014-09-01Not applicableUs
Klor-Con MTablet, extended release750 mg/1OralAphena Pharma Solutions Tennessee, Inc.2011-01-18Not applicableUs
Klor-con MTablet, extended release1500 mg/1OralSandoz2014-09-01Not applicableUs
Klor-con MTablet, extended release1500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-09-01Not applicableUs
Klor-Con MTablet, extended release10 meq/1OralCardinal Health2011-01-182015-12-29Us
Klor-con MTablet, extended release1500 mg/1OralCardinal Health2014-09-01Not applicableUs
Klor-con MTablet, extended release1125 mg/1OralSandoz2014-09-01Not applicableUs
Klor-Con MTablet, extended release750 mg/1OralMc Kesson Contract Packaging2011-12-07Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hi Potency Potassium ChlorideTablet, extended release500 mgOralSwiss Herbal Remedies Ltd.1997-02-242001-08-02Canada
Kaochlor-20Solution3 gOralPfizer1995-12-312006-08-02Canada
Micro-K-10 Extencaps Src 750mgCapsule, extended release750 mgOralWyeth Ayerst Canada Inc.1994-12-312003-07-28Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HUMCO Potassium Chloride Oral Solution 10%Liquid100 mg/mLOralHumco Holding Group. Inc.1979-01-012016-10-13Us
K-SolLiquid40 meq/15mLOralLaser Pharmaceuticals Llc2015-01-222015-12-31Us
K-SolLiquid20 meq/15mLOralLaser Pharmaceuticals Llc2015-01-222015-12-31Us
Klor-ConPowder, for solution1.5 g/1OralUpsher Smith Laboratories2009-11-012017-06-20Us
Klor-conPowder, for solution1.5 g/1OralSandoz2014-09-012017-06-20Us
Klor-ConPowder, for solution1.875 g/1OralUpsher Smith Laboratories2009-11-012017-06-20Us
Klor-ConPowder, for solution20 meq/1OralCardinal Health2009-11-01Not applicableUs
Klor-conPowder, for solution1.5 g/1OralUpsher Smith Laboratories, Llc2017-10-23Not applicableUs
Klor-con/25Powder, for solution1.875 g/1OralSandoz2014-09-012017-06-20Us
Potassium ChloridePowder, for solution25 meq/1OralVirtus Pharmaceuticals2014-06-132017-07-01Us
International/Other Brands
Kaon Cl / Kaon-CL 10 / Klor-CON / Klotrix / Micro-K / Sando-K / Slow-K
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
(20 Mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USPPotassium Chloride (150 mg) + Glucose (3.3 g) + Sodium Chloride (300 mg)SolutionIntravenousBaxter Laboratories1978-12-31Not applicableCanada
(20 Mmol/l) Potassium Chloride In 5% Dextrose and 0.9% Sodium Chloride Injection USPPotassium Chloride (150 mg) + Glucose (5 g) + Sodium Chloride (900 mg)SolutionIntravenousBaxter Laboratories1990-12-31Not applicableCanada
(20 Mmol/l) Potassium Chloride In 5% Dextrose Injection USPPotassium Chloride (150 mg) + Glucose (5 g)LiquidIntravenousBaxter Laboratories1989-12-31Not applicableCanada
(20mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USPPotassium Chloride (150 mg) + Sodium Chloride (900 mg)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada
(20mmol/l) Potassium Chloride In 5% Dextrose and 0.2% Sodium Chloride Injection USPPotassium Chloride (150 mg) + Glucose (5 g) + Sodium Chloride (200 mg)SolutionIntravenousBaxter Laboratories1989-12-312016-07-15Canada
(20mmol/l) Potassium Chloride In 5% Dextrose and 0.45% Sodium Chloride Injection USPPotassium Chloride (150 mg) + Glucose (5 g) + Sodium Chloride (450 mg)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada
(40 Mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USPPotassium Chloride (300 mg) + Sodium Chloride (900 mg)LiquidIntravenousBaxter Laboratories1989-12-31Not applicableCanada
(40 Mmol/l) Potassium Chloride In 5% Dextrose Injection USPPotassium Chloride (300 mg) + Glucose (5 g)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada
(40 Mmols/l) Potassium Chloride In Lactated Ringer's Injection USPPotassium Chloride (328 mg) + Calcium Chloride (20 mg) + Sodium lactate (310 mg) + Sodium Chloride (600 mg)SolutionIntravenousBaxter Laboratories2002-12-112016-07-15Canada
(40mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USPPotassium Chloride (300 mg) + Glucose (3.3 g) + Sodium Chloride (300 mg)SolutionIntravenousBaxter Laboratories1978-12-31Not applicableCanada
Categories
UNII
660YQ98I10
CAS number
7447-40-7
Weight
Average: 74.551
Monoisotopic: 73.932559568
Chemical Formula
ClK
InChI Key
WCUXLLCKKVVCTQ-UHFFFAOYSA-M
InChI
InChI=1S/ClH.K/h1H;/q;+1/p-1
IUPAC Name
potassium chloride
SMILES
[Cl-].[K+]

Pharmacology

Indication

For use as an electrolyte replenisher and in the treatment of hypokalemia.

Structured Indications
Pharmacodynamics

The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

Mechanism of action

Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.

TargetActionsOrganism
USolute carrier family 12 member 2Not AvailableHuman
USolute carrier family 12 member 1
binder
Human
USolute carrier family 12 member 5Not AvailableHuman
USolute carrier family 12 member 6Not AvailableHuman
USolute carrier family 12 member 7Not AvailableHuman
USolute carrier family 12 member 4Not AvailableHuman
Absorption

Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Potassium is a normal dietary constituent and, under steady-state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.

Half life
Not Available
Clearance
Not Available
Toxicity

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AclidiniumAclidinium may increase the ulcerogenic activities of Potassium Chloride.Approved
AlcuroniumAlcuronium may increase the ulcerogenic activities of Potassium Chloride.Experimental
Anisotropine MethylbromideAnisotropine Methylbromide may increase the ulcerogenic activities of Potassium Chloride.Approved
AtracuriumAtracurium may increase the ulcerogenic activities of Potassium Chloride.Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the ulcerogenic activities of Potassium Chloride.Approved
AtropineAtropine may increase the ulcerogenic activities of Potassium Chloride.Approved, Vet Approved
BenactyzineBenactyzine may increase the ulcerogenic activities of Potassium Chloride.Withdrawn
BenzatropineBenzatropine may increase the ulcerogenic activities of Potassium Chloride.Approved
BiperidenBiperiden may increase the ulcerogenic activities of Potassium Chloride.Approved, Investigational
BornaprineBornaprine may increase the ulcerogenic activities of Potassium Chloride.Experimental
ButylscopolamineScopolamine butylbromide may increase the ulcerogenic activities of Potassium Chloride.Approved, Vet Approved
ChlorphenoxamineChlorphenoxamine may increase the ulcerogenic activities of Potassium Chloride.Withdrawn
CyclopentolateCyclopentolate may increase the ulcerogenic activities of Potassium Chloride.Approved
DarifenacinDarifenacin may increase the ulcerogenic activities of Potassium Chloride.Approved, Investigational
DesloratadineDesloratadine may increase the ulcerogenic activities of Potassium Chloride.Approved, Investigational
DexetimideDexetimide may increase the ulcerogenic activities of Potassium Chloride.Withdrawn
DicyclomineDicyclomine may increase the ulcerogenic activities of Potassium Chloride.Approved
EmeproniumEmepronium may increase the ulcerogenic activities of Potassium Chloride.Experimental
EtanautineEtanautine may increase the ulcerogenic activities of Potassium Chloride.Experimental
EthopropazineEthopropazine may increase the ulcerogenic activities of Potassium Chloride.Approved
EtybenzatropineEtybenzatropine may increase the ulcerogenic activities of Potassium Chloride.Experimental
FesoterodineFesoterodine may increase the ulcerogenic activities of Potassium Chloride.Approved
GallamineGallamine may increase the ulcerogenic activities of Potassium Chloride.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the ulcerogenic activities of Potassium Chloride.Approved
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Potassium Chloride.Approved, Investigational, Vet Approved
HexamethoniumHexamethonium may increase the ulcerogenic activities of Potassium Chloride.Experimental
HomatropineHomatropine may increase the ulcerogenic activities of Potassium Chloride.Approved
HyoscyamineHyoscyamine may increase the ulcerogenic activities of Potassium Chloride.Approved
Ipratropium bromideIpratropium bromide may increase the ulcerogenic activities of Potassium Chloride.Approved
MazaticolMazaticol may increase the ulcerogenic activities of Potassium Chloride.Experimental
MecamylamineMecamylamine may increase the ulcerogenic activities of Potassium Chloride.Approved
MethanthelineMethantheline may increase the ulcerogenic activities of Potassium Chloride.Approved, Investigational
Methylscopolamine bromideMethylscopolamine bromide may increase the ulcerogenic activities of Potassium Chloride.Approved
MetixeneMetixene may increase the ulcerogenic activities of Potassium Chloride.Approved
OrphenadrineOrphenadrine may increase the ulcerogenic activities of Potassium Chloride.Approved
OtiloniumOtilonium may increase the ulcerogenic activities of Potassium Chloride.Experimental, Investigational
OxitropiumOxitropium may increase the ulcerogenic activities of Potassium Chloride.Investigational
OxybutyninOxybutynin may increase the ulcerogenic activities of Potassium Chloride.Approved, Investigational
OxyphenoniumOxyphenonium may increase the ulcerogenic activities of Potassium Chloride.Approved
PancuroniumPancuronium may increase the ulcerogenic activities of Potassium Chloride.Approved
PentoliniumPentolinium may increase the ulcerogenic activities of Potassium Chloride.Approved
PhenglutarimidePhenglutarimide may increase the ulcerogenic activities of Potassium Chloride.Experimental
PipecuroniumPipecuronium may increase the ulcerogenic activities of Potassium Chloride.Approved
PirenzepinePirenzepine may increase the ulcerogenic activities of Potassium Chloride.Approved
ProcyclidineProcyclidine may increase the ulcerogenic activities of Potassium Chloride.Approved
PropanthelinePropantheline may increase the ulcerogenic activities of Potassium Chloride.Approved
PropiverinePropiverine may increase the ulcerogenic activities of Potassium Chloride.Approved, Investigational
QuinidineQuinidine may increase the ulcerogenic activities of Potassium Chloride.Approved
ScopolamineScopolamine may increase the ulcerogenic activities of Potassium Chloride.Approved
SolifenacinSolifenacin may increase the ulcerogenic activities of Potassium Chloride.Approved
TiotropiumTiotropium may increase the ulcerogenic activities of Potassium Chloride.Approved
TolterodineTolterodine may increase the ulcerogenic activities of Potassium Chloride.Approved, Investigational
TrihexyphenidylTrihexyphenidyl may increase the ulcerogenic activities of Potassium Chloride.Approved
TrimethaphanTrimethaphan may increase the ulcerogenic activities of Potassium Chloride.Approved, Investigational
TropatepineTropatepine may increase the ulcerogenic activities of Potassium Chloride.Experimental
TropicamideTropicamide may increase the ulcerogenic activities of Potassium Chloride.Approved
TrospiumTrospium may increase the ulcerogenic activities of Potassium Chloride.Approved
TubocurarineTubocurarine may increase the ulcerogenic activities of Potassium Chloride.Approved
UmeclidiniumUmeclidinium may increase the ulcerogenic activities of Potassium Chloride.Approved
VecuroniumVecuronium may increase the ulcerogenic activities of Potassium Chloride.Approved
Food Interactions
  • Take with a full glass of water Take after a full meal.

References

Synthesis Reference

Fritz Hagedorn, Gerd Peuschel, Arno Singewald, "Method for the production of potassium chloride with K.sub.2 O content of more than 55 weight percent." U.S. Patent US5057208, issued July, 1955.

US5057208
General References
Not Available
External Links
KEGG Drug
D02060
PubChem Compound
4873
PubChem Substance
46506038
ChemSpider
4707
ChEBI
32588
ChEMBL
CHEMBL1200731
Therapeutic Targets Database
DAP000828
PharmGKB
PA451055
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Potassium_Chloride
ATC Codes
B05XA01 — Potassium chlorideA12BA51 — Potassium chloride, combinationsA12BA01 — Potassium chloride
AHFS Codes
  • 40:34.00* — Hemodialysis Solution
  • 88:29.00* — Minerals
  • 40:12.00 — Replacement Preparations
FDA label
Download (632 KB)
MSDS
Download (72.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDiagnosticHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentGastric Emptying / Healthy Volunteers1
1, 2CompletedOtherGlaucoma1
1, 2CompletedSupportive CareHypertensive / Pre-Hypertension1
1, 2CompletedTreatmentArterial Hypotension / Arterial hypoxia1
1, 2CompletedTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Problems1
1, 2RecruitingPreventionAtherosclerosis1
2Active Not RecruitingPreventionAcute Kidney Injury (AKI)1
2Active Not RecruitingTreatmentCardiopulmonary Bypass / Surgery, Cardiac1
2Active Not RecruitingTreatmentRespiratory Distress Syndrome, Adult1
2CompletedOtherBowel preparation therapy1
2CompletedTreatmentAcidosis, Respiratory / Shock, Hemorrhagic / Traumatic Shock1
2CompletedTreatmentBlood Loss,Surgical / General Surgery / Prostate Cancer1
2CompletedTreatmentBone Diseases / Metabolic Acidosis / Mineral Metabolism / Physical Capacity / Renal Transplant Patients1
2CompletedTreatmentCataracts1
2CompletedTreatmentColonoscopy1
2CompletedTreatmentDiastolic Heart Failure / Heart Failure, Unspecified1
2CompletedTreatmentDysmenorrhea / Endometriosis1
2CompletedTreatmentMalignant Neoplasm of Colon1
2CompletedTreatmentNeoplasms, Brain1
2CompletedTreatmentSymptomatic Focal Vitreomacular Adhesion1
2Not Yet RecruitingOtherColon Prep for Colonoscopy1
2RecruitingNot AvailablePain1
2RecruitingPreventionHypertensive1
2RecruitingPreventionPancreatoduodenectomy1
2RecruitingTreatmentAnterior Wall Myocardial Infarction1
2RecruitingTreatmentHeart Failure, Unspecified1
2RecruitingTreatmentHypertensive1
2, 3CompletedTreatmentGlaucoma1
3CompletedNot AvailableBowel Preparation for Colonoscopy1
3CompletedNot AvailableColonoscopy1
3CompletedDiagnosticBowel Preparation for Colonoscopy1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedSupportive CareColon Adenomas / Colorectal Cancers1
3CompletedSupportive CareColonic Diseases / Diabetes Mellitus (DM)1
3CompletedTreatmentBowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel1
3CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Hypertensive1
3CompletedTreatmentCataracts2
3CompletedTreatmentColon Diseases / Colonoscopy Preparation1
3CompletedTreatmentColon Polyps / Colorectal Polyps / Crohn's Disease (CD) / Diverticulitis / Malignant Neoplasm of Colon / Rectal Carcinoma / Ulcerative Colitis (UC)1
3CompletedTreatmentColonoscopy3
3CompletedTreatmentMalignant Neoplasm of Colon1
3CompletedTreatmentOccasional Constipation1
3RecruitingOtherDigestive System Diseases1
3RecruitingTreatmentHealthy Volunteers1
3Unknown StatusDiagnosticColonoscopy1
4CompletedNot AvailableColonoscopy1
4CompletedBasic ScienceFunctional Constipation / Irritable Bowel Syndrome Characterized by Constipation1
4CompletedPreventionInflammatory Reaction1
4CompletedScreeningColorectal Cancers1
4CompletedTreatmentArthrocentesis / Pain / Temporomandibular Joint Dysfunction1
4CompletedTreatmentBowel Preparation for Colonoscopy1
4CompletedTreatmentColonoscopy3
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentCritically Ill / Surgery, Cardiac / Thoracic Surgery1
4CompletedTreatmentEndocrine ophthalmopathy1
4CompletedTreatmentGastrointestinal Diseases1
4CompletedTreatmentMalignant Neoplasm of Colon1
4CompletedTreatmentPreparation for Colonoscopy1
4Not Yet RecruitingDiagnosticBowel Preparation Solutions1
4Not Yet RecruitingHealth Services ResearchColorectal Cancers1
4Not Yet RecruitingTreatmentEmergency / Fluid Loss / Symptom Complex, Triple1
4RecruitingTreatmentAtrial Flutter / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentHypovolaemia1
4RecruitingTreatmentSubjets Requiring a Colonoscopy1
4TerminatedTreatmentDepression / Depression, Myalgia1
4Unknown StatusHealth Services ResearchColonoscopy1
4Unknown StatusTreatmentAcute Hypokalemia1
4Unknown StatusTreatmentTraumas1
Not AvailableActive Not RecruitingDiagnosticDiabetes Mellitus (DM)1
Not AvailableCompletedNot AvailableEffectiveness of SMS to Fix PC Interval1
Not AvailableCompletedNot AvailableHyponatremias1
Not AvailableCompletedNot AvailableSpinal Cord Injuries (SCI)1
Not AvailableCompletedNot AvailableThe Timing of Bowel Preparation in Outpatient Colonoscopy1
Not AvailableCompletedTreatmentCataracts1
Not AvailableCompletedTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portosystemic Encephalopathy / PSE1
Not AvailableEnrolling by InvitationTreatmentAnaesthesia therapy1
Not AvailableNot Yet RecruitingScreeningActual Impaired Fluid Volume1
Not AvailableNot Yet RecruitingTreatmentChromosome Abnormalities / Twin Pregnancy With Antenatal Problem1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableRecruitingHealth Services ResearchAcute Kidney Injury (AKI)1
Not AvailableRecruitingPreventionHypertensive1
Not AvailableRecruitingScreeningColonoscopy1
Not AvailableRecruitingTreatmentKetoacidosis, Diabetic1
Not AvailableRecruitingTreatmentShock / Shock, Septic1
Not AvailableTerminatedPreventionBlood Pressures1
Not AvailableUnknown StatusDiagnosticBowel Preparation for Colonoscopy1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1
Not AvailableWithdrawnTreatmentAltered Mental Status / AMS / HE / Hepatic Encephalopathy / Liver Cirrhosis1

Pharmacoeconomics

Manufacturers
  • Novo nordisk inc
  • Savage laboratories inc div altana inc
  • Kv pharmaceutical co
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
  • Abraxis pharmaceutical products
  • Akorn inc
  • App pharmaceuticals llc
  • B braun medical inc
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp
  • Gd searle llc
  • Hospira inc
  • International medication system
  • Eli lilly and co
  • Luitpold pharmaceuticals inc
  • Miles laboratories inc
  • Pharma serve inc sub torigian laboratories
  • Watson laboratories inc
  • Future pak ltd
  • Upsher smith laboratories inc
  • Apothecon inc div bristol myers squibb
  • Abbott laboratories pharmaceutical products div
  • Copley pharmaceutical inc
  • Eurand america inc
  • Schering corp
  • Novartis pharmaceuticals corp
  • Upsher-Smith Laboratories Inc.
Packagers
Dosage forms
FormRouteStrength
LiquidHemodialysis
TabletOral
Powder, for solutionIntraocular
SolutionIntraocular
Kit; powder, for solution; tablet, delayed releaseOral
Kit; solutionIntraocular
SolutionIntra-arterial
Powder, for solutionNasogastric
PowderOral
SolutionIntrathecal
SolutionOphthalmic
SolutionUnknown
Tablet, extended releaseOral500 mg
LiquidOral100 mg/mL
LiquidIntraocular
LiquidHemodialysis251.6 g
LiquidOral750 mg
Powder, for solutionOral1.5 g
Tablet, extended releaseOral1.5 g
Powder, for solutionOral1.86 g
TabletOral900 mg
LiquidOral20 meq/15mL
Tablet, extended releaseOral750 mg
SolutionOral10 %
SolutionOral3 g
SolutionOral200 mg
Powder, for solutionOral1.5 g/1
Powder, for solutionOral1.875 g/1
Powder, for solutionOral20 meq/1
Tablet, extended releaseOral600 mg/1
Tablet, extended releaseOral1125 mg/1
Tablet, extended releaseOral750 mg/1
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral20 meq/1
SolutionIrrigation
LiquidIrrigation
Injection, solutionIntravenous
Capsule, extended releaseOral600 mg
Capsule, extended releaseOral750 mg
LiquidBuccal
SprayBuccal
Kit
SolutionHemodialysis
Kit; solutionIntraocular; Irrigation
Granule, effervescentOral
Tablet, extended releaseOral600 mg
SolutionOral
LiquidOral
EmulsionIntravenous
Injection, solutionIntra-arterial
Solution
Powder, for solutionOral
Capsule, coated, extended releaseOral10 meq/1
Capsule, coated, extended releaseOral8 meq/1
Capsule, extended releaseOral600 mg/1
Capsule, extended releaseOral750 mg/1
InjectionIntravenous149 mg/mL
Injection, solutionIntravenous10 meq/100mL
Injection, solutionIntravenous14.9 g/1000mL
Injection, solutionIntravenous200 meq/1000mL
Injection, solutionIntravenous22.4 g/1000mL
Injection, solutionIntravenous29.8 g/1000mL
Injection, solutionIntravenous30 meq/100mL
Injection, solutionIntravenous400 meq/1000mL
Injection, solutionIntravenous7.46 g/1000mL
Injection, solution, concentrateIntravenous149 mg/mL
Injection, solution, concentrateIntravenous2 meq/mL
Injection, solution, concentrateParenteral14.9 g/100mL
LiquidOral40 meq/30mL
LiquidOral40 meq/15mL
PowderOral20 meq/1.5g
Powder, for solutionOral1.5 g/1.58g
Powder, for solutionOral1.5 g/1.74g
Powder, for solutionOral25 meq/1
SolutionOral1.5 g/15mL
SolutionOral20 meq/15mL
SolutionOral3 g/15mL
SolutionOral40 meq/15mL
SolutionOral40 meq/30mL
Tablet, extended releaseOral1500 mg/1
Tablet, extended releaseOral8 meq/1
Tablet, film coated, extended releaseOral10 meq/1
Tablet, film coated, extended releaseOral1500 mg/1
Tablet, film coated, extended releaseOral600 mg/1
Tablet, film coated, extended releaseOral750 mg/1
Tablet, film coated, extended releaseOral8 meq/1
PowderHemodialysis12.5 g
PowderHemodialysis13 g
PowderHemodialysis15.26 g
PowderHemodialysis25 g
PowderHemodialysis7.65 g
TabletOral20 meq/1
CapsuleOral600 mg/1
CapsuleOral750 mg/1
Capsule, extended releaseOral10 meq/1
Capsule, extended releaseOral8 meq/1
SolutionIntravenous149 mg
SolutionIntravenous2 meq
InjectionIntravenous
LiquidIntravenous
SolutionIntravenous
SolutionIntravenous20 meq
LiquidIntravenous2 meq
SolutionIntravenous1.784 mg
SolutionIntravenous2.384 mg
LiquidIntravenous149 mg
LiquidIntravenous14.9 mg
LiquidIntravenous22.4 mg
LiquidIntravenous29.8 mg
LiquidIntravenous7.46 mg
PowderHemodialysis6.2 g
Tablet, effervescentOral
SolutionHemodialysis; Intravenous
DoucheVaginal
IrrigantIrrigation
LiquidOral10 %
AerosolOral
LiquidIntravenous150 mg
KitOral
Injection, solution, concentrateIntravenous
Powder, for solutionNasogastric; Oral
Prices
Unit descriptionCostUnit
Klor-Con 100 20meq Packets Box106.77USD box
Kay Ciel 30 20meq Packets Box58.99USD box
Rum-K-SF 15% Liquid 473ml Bottle45.98USD bottle
Klor-Con 30 25meq Packets Box36.99USD box
Colyte 240 gm Solution26.0USD bottle
Colyte-Flavored 240 gm Solution18.17USD bottle
K-Lor 20meq Packets1.92USD packet
K-lyte tablet eff1.43USD tablet
K-lyte-cl 25 meq tablet eff1.43USD tablet
Micro-K 10meq capsule1.41USD capsule
Micro-K 8meq capsule1.21USD capsule
Potassium cl 25 meq tablet eff0.94USD tablet
Micro-k 10 meq extencaps0.91USD each
Potassium Chloride CR 10meq capsule0.9USD capsule
Potassium Chloride CR 8meq capsule0.87USD capsule
K-Tabs 10meq Controlled Release Tabs0.68USD tab
K-tab er 10 meq tablet0.66USD tablet
Kaochlor-eff 20 meq tablet0.59USD tablet
K-tab 10 meq tablet sa0.58USD tablet
K-Lyte 25 meq Effervescent Tablet0.58USD tablet
Klor-con m20 tablet0.57USD tablet
Klor-Con/EF 25meq Effervescent Tabs0.57USD tab
Klor-Con 8meq Controlled Release Tabs0.56USD tab
Klor-Con M20 20meq Controlled Release Tabs0.55USD tab
Potassium Chloride Crys CR 20meq Controlled Release Tabs0.53USD tab
Potassium cl 20 meq tablet er0.52USD tablet
Potassium cl 20 meq tablet sa0.52USD tablet
Klor-con 10 meq tablet0.5USD tablet
Klor-con m15 tablet0.5USD tablet
Klotrix 10meq Controlled Release Tabs0.5USD tab
Potassium cl er 20 meq tablet0.49USD tablet
Klor-con-ef 25 meq tablet eff0.4USD tablet
Micro-k 8 meq extencaps0.34USD each
Kaon-Cl-10 10meq Controlled Release Tabs0.3USD tab
Klor-con m10 tablet0.3USD tablet
Potassium cl er 10 meq tablet0.3USD tablet
Potassium cl 10 meq tablet sa0.29USD tablet
Potassium Chloride Crys CR 10meq Controlled Release Tabs0.28USD tab
Potassium Chloride CR 10meq Controlled Release Tabs0.27USD tab
Potassium cl er 8 meq tablet0.26USD tablet
Kaon-cl 10 meq tablet sa0.23USD tablet
Potassium cl 2 meq/ml vial0.23USD ml
K-Dur 20 meq Sustained-Release Tablet0.21USD tablet
Potassium Chloride CR 8meq Controlled Release Tabs0.18USD tab
Klor-con 8 meq tablet0.16USD tablet
Slow K 8 meq Sustained-Release Tablet0.16USD tablet
Micro-K Extencaps 8 meq Sustained-Release Capsule0.1USD capsule
Apo-K 8 meq Sustained-Release Tablet0.09USD tablet
Potassium Chloride 40 Meq/15ml(20%) Liquid0.06USD ml
Potassium Chloride 20 Meq/15ml(10%) Liquid0.03USD ml
Potassium chloride crystals0.02USD g
K-10 Oral Liquid 1.33 meq/ml Liquid0.02USD ml
Colyte with flavor packets0.01USD ml
Pms - Potassium Chloride 1.33 meq/ml Liquid0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7291324No2002-10-222022-10-22Us
US7169381No2004-09-012024-09-01Us
US7658914No2004-09-012024-09-01Us
US7084130No2001-11-292021-11-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)770 °CNot Available
water solubilityFreely solubleNot Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
pKa (Strongest Acidic)-7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9445
Blood Brain Barrier+0.975
Caco-2 permeable+0.6764
P-glycoprotein substrateNon-substrate0.9039
P-glycoprotein inhibitor INon-inhibitor0.9891
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9219
CYP450 2C9 substrateNon-substrate0.8116
CYP450 2D6 substrateNon-substrate0.717
CYP450 3A4 substrateNon-substrate0.7571
CYP450 1A2 substrateNon-inhibitor0.7551
CYP450 2C9 inhibitorNon-inhibitor0.8594
CYP450 2D6 inhibitorNon-inhibitor0.9314
CYP450 2C19 inhibitorNon-inhibitor0.8365
CYP450 3A4 inhibitorNon-inhibitor0.9576
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9002
Ames testNon AMES toxic0.6808
CarcinogenicityCarcinogens 0.7523
BiodegradationReady biodegradable0.6815
Rat acute toxicity1.9786 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9433
hERG inhibition (predictor II)Non-inhibitor0.9634
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkali metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal salts
Sub Class
Alkali metal chlorides
Direct Parent
Alkali metal chlorides
Alternative Parents
Inorganic chloride salts
Substituents
Alkali metal chloride / Inorganic chloride salt / Inorganic salt
Molecular Framework
Not Available
External Descriptors
potassium salt, inorganic chloride (CHEBI:32588)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [PubMed:12920401]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [PubMed:16093448]
  4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [PubMed:16713495]
  5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [PubMed:16807401]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
Gene Name
SLC12A5
Uniprot ID
Q9H2X9
Uniprot Name
Solute carrier family 12 member 5
Molecular Weight
126182.49 Da
References
  1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [PubMed:17134779]
  2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [PubMed:16936706]
  3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [PubMed:17008020]
  5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Rubidium ion transmembrane transporter activity
Specific Function
Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
Gene Name
SLC12A6
Uniprot ID
Q9UHW9
Uniprot Name
Solute carrier family 12 member 6
Molecular Weight
127615.745 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
Gene Name
SLC12A7
Uniprot ID
Q9Y666
Uniprot Name
Solute carrier family 12 member 7
Molecular Weight
119104.84 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
Gene Name
SLC12A4
Uniprot ID
Q9UP95
Uniprot Name
Solute carrier family 12 member 4
Molecular Weight
120648.73 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [PubMed:12920401]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [PubMed:16093448]
  4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [PubMed:16713495]
  5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [PubMed:16807401]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
Gene Name
SLC12A5
Uniprot ID
Q9H2X9
Uniprot Name
Solute carrier family 12 member 5
Molecular Weight
126182.49 Da
References
  1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [PubMed:17134779]
  2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [PubMed:16936706]
  3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [PubMed:17008020]
  5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Rubidium ion transmembrane transporter activity
Specific Function
Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
Gene Name
SLC12A6
Uniprot ID
Q9UHW9
Uniprot Name
Solute carrier family 12 member 6
Molecular Weight
127615.745 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
Gene Name
SLC12A7
Uniprot ID
Q9Y666
Uniprot Name
Solute carrier family 12 member 7
Molecular Weight
119104.84 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
Gene Name
SLC12A4
Uniprot ID
Q9UP95
Uniprot Name
Solute carrier family 12 member 4
Molecular Weight
120648.73 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]

Drug created on June 13, 2005 07:24 / Updated on November 22, 2017 12:31